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     INTRODUCTION 
  Praziquantel is used to treat all forms of schistosomiasis. 
The drug was introduced in clinical practice in the late 1970s, 
and its chemistry      , clinical efficacy, and side effects have been 
extensively reviewed.  1,  2   The antischistosomal effects of prazi-
quantel in animals were published in 1977, and the effects in 
humans were published in 1978.  3–  5   Early clinical trials carried 
out for   Schistosoma japonicum ,   S. mansoni  , and   S. haemato-
bium   found praziquantel to be highly effective across a wide 
spectrum of schistosomes.  6–  8   Additionally, on a per-case basis, 
treatment with praziquantel is inexpensive. It currently costs 
around US$0.40 or less to treat a case of schistosomiasis.  2   All 
of these factors have made praziquantel treatments one of the 
most important strategies to reduce the morbidity associated 
with chronic schistosomiasis. 
  Before the widespread use of praziquantel (called pyqui-
ton) in China, the national control program for schistoso-
miasis established in 1955 focused largely on interrupting 
transmission of infection through environmental manage-
ment and identifying strategies that would work in different 
regional settings (the plains, mountainous, and hilly areas ver-
sus marshland and lake regions).  9   Control strategies consisted 
of snail control, identifying infected humans and other animal 
reservoirs, and use of antimonials such as potassium antimony 
tartrate or fouadin initially and later, the non-antimonial 
furapromidum. The antimonials were quite toxic, and the non-
antimonials had suboptimal safety profiles. Therefore, none of 
these drugs were used for large-scale chemotherapy.  10  
  Praziquantel saw widespread use in China during the 
10-year World Bank Loan Program starting in 1992.  11–  13   Large-
scale administrations of praziquantel were implemented for 
both human and bovines for morbidity control with the aim 
of reducing   S. japonicum   prevalence in both populations by 
at least 40%. Different strategies were used in different areas 
for chemotherapy administration depending on regional dif-
ferences in infection prevalence: mass treatment of the entire 
population aged 5–65 years without preliminary screening for 
high-endemic regions, selective treatment of persons identified 
through diagnosis to be infected in medium-endemic regions, 
and phased treatment using mass and selective treatment in 
sequence as regions transition from high to lower endemic-
ity.  10   In many cases, chemotherapy was combined with other 
key strategies to sustain transmission control, including health 
education and snail control through environmental manage-
ment and limited mollusciciding. The program resulted in dra-
matic reductions in schistosomiasis in China.  11–  13  
  Current recommended human dosages of praziquantel to 
treat schistosomiasis are based on weight of the human host 
(40 mg per kg body weight). Using recommended dosages, 
cure rates of 80–90% have been documented for   S. japoni-
cum . 14   However, schistosomes are generally only sensitive 
to praziquantel during their earliest stage as schistosomula, 
which is a few days after infection, and then, during their later 
stage beginning around weeks 6–7 after infection.  1   The  lack 
of efficacy against juvenile schistosomes has lead to develop-
ment and occasional but rare use of other drugs, such as arte-
mether, which is effective against the juvenile stages of the 
parasite.  11,  15  
  Little evidence exists on the potential praziquantel resis-
tance of   S. japonicum  . Ross and others  11   state that, despite 
minor side effects (nausea, dizziness, rash, and pruritus), there 
have been no fatalities associated with praziquantel treatment, 
and there has not been unequivocal evidence that schistosomes 
have developed drug resistance. Cure rates are relatively high 
(70–90%), with those not cured still benefiting from reduced 
egg counts. 
  There is evidence to suggest that   S. japonicum   may be 
generally more susceptible to praziquantel than other schis-
tosome species.  16   However, factors such as widespread and 
indiscriminant use of praziquantel with little prior diagnosis 
and the potential for decreasing compliance with drug dosages 
because of treatment fatigue, poor education, and indifference 
to chronic infection suggest the need for careful consideration 
as to whether praziquantel resistance may be developing in 
China. 
  Recent studies have established an   in vitro   test of potential 
praziquantel resistance based on computing the effective con-
centration at which 50% of the miracidial form of the parasite 
becomes inactivated (EC  50 ). 17   The method has shown higher 
EC  50   levels for purported difficult-to-treat strains of   S. man-
soni  . Despite laboratory assessments of resistance to praziqu-
antel, there remains debate whether resistance results in any 
practical challenges for everyday disease control efforts. 
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  In this paper, we present the results of a cross-sectional 
infection survey conducted in 33 villages in an endemic region 
of Sichuan, China, which has undergone intense chemother-
apy treatment for nearly a decade. Miracidia hatched from 
infected individuals’ stool samples were subjected to an   in 
vitro   assay of praziquantel susceptibility. Additionally, infected 
persons were treated and retested for infection to determine 
the proportion of treatment failures, which is another indica-
tor of resistance. Based on a survey of 60 households, we docu-
ment some of the factors that may contribute to resistance and 
treatment failures in this region of China. 
   METHODS 
  Study  area.     Our study was conducted in one township 
within a schistosomiasis-endemic county of southwest Sichuan 
province, which is representative of the hilly and mountainous 
transmission ecology of China. The township consists of 
three administrative villages that are further divided into 33 
natural villages, which collectively account for a population 
of approximately 5,860 persons (based on official resident 
records). Administrative villages are subdivided into natural 
villages, also known as production groups, which are the 
smallest level of organization in rural China. The majority of 
the population is farmers, who grow tobacco and flowers in the 
spring season and wheat and beans in the fall season, although 
aquaculture is prevalent in some villages. 
  Previous research conducted in this region has documented 
the risk factors associated with transmission, including the rela-
tionships between infection and cercarial exposure and other 
environmental determinants of transmission.  18,  19   Four of the 
current selections of natural villages were part of the previous 
study. Increasing use of chemotherapy to reach disease control 
targets has motivated our group to revisit this study area to 
assess praziquantel compliance and efficacy. In 2000, the prev-
alence of infection as determined by positive result on either 
the miracidial hatch or the Kato–Katz examination in 4 of 33 
natural villages in the township was found to range from 44% 
to 73%.  18   After treatment, in 2002, a reassessment of infection 
found that prevalence had decreased to 23–38%.  19   Successive 
chemotherapy administrations, snail control, and introduction 
of biogas into the region have resulted in the declaration of 
transmission control in the region (all of Sichuan Province) in 
2008. The national criterion for transmission control is defined 
as < 1% infection in human and cattle, no new infections in 
children and young cattle, no acute cases, and snail habitat 
reduced by 98% of historical levels. Our cross-sectional sur-
vey described below provides an independent confirmation of 
the control achievement. At the request of our Chinese collab-
orators, who are sensitive to the release of detailed infection 
data from a region that has been officially declared to have 
attained transmission control, we have withheld the names 
and exact locations of the villages in this study. 
   Parasitological  examinations.     In November of 2009, all 
individuals aged 6 years and older from the 33 natural villages 
(also called production groups) in the study area were asked 
to participate in a cross-sectional infection survey. With 
written informed consent, a stool sample was collected from 
each participant. The stool was first examined for presence 
of infection using the miracidial hatch test. Briefly, the hatch 
test consists of straining 30 g of a subject’s stool through nylon 
mesh to isolate parasite eggs, which are then incubated in 
an Erlenmeyer flask of dechlorinated water at 28–30°C and 
observed at regular intervals for up to 8 hours for the presence 
of hatched miracidia. For individuals found to be hatch test-
positive, a subsequent Kato–Katz fecal smear test (for each 
person, one homogenized stool sample and three 41.7-mg 
slides) was conducted to quantify egg excretion (in units of 
eggs per gram of feces [EPG]).  20  
  All infected individuals were treated with two times the 
recommended dosage of praziquantel (40 mg/kg) for approx-
imately 2 and 3 weeks after the infection survey. After an addi-
tional week (approximately 1 month after the initial infection 
survey), individuals were retested for infection using the hatch 
test. Those found to be infected were retreated until infec-
tion was not found. Although praziquantel has a biphasic effi-
cacy period and it has been recommended that treatments be 
staged 3 weeks apart, in our case, the examinations were con-
ducted in the winter season when snails do not shed cercariae, 
transmission is negligible, and hence, infection with juvenile 
parasites unlikely.  21   Furthermore, because transmission is neg-
ligible, residual infection is likely to result from treatment fail-
ure rather than advancement of new juvenile infections. 
    In vitro   praziquantel assay.     Based on the methods of Liang 
and others  16   and Botros and others  17  , a miracidial assay was 
used to determine the effective concentrations of praziquantel 
at which 50% of the parasites would change shape (EC  50 ),  an 
indicator of sensitivity to the drug. Because of low numbers of 
parasites per host sample, all available miracidia were collected 
from the hatch tests of all infected individuals and combined. 
Miracidia were placed into 24-well flat-bottom microplates. 
  A praziquantel solution was prepared by dissolving       prazi-
quantel (Nanjing Pharmaceutical Factory, Nanjing, Jiangsu, 
China) in dimethyl sulfoxide (DMSO) to create a 10 mM 
stock solution. Serial dilutions were performed to create solu-
tions at 10  −8 ,  10 −7 ,  10 −6  , and 10  −5   M concentrations. Because the 
number of miracidia was generally low, we were only able to 
test small numbers of miracidia at each concentration. At least 
five miracidia were exposed for 10 minutes at each concen-
tration. At least 20 miracidia were exposed at the two middle 
concentrations. Miracidia were also exposed with two con-
trols: praziquantel-free 10  −3   M DMSO and decholorinated 
water. Miracidia were observed at 1-minute intervals, and the 
number that underwent morphological changes indicative of 
sensitivity to praziquantel was counted.  16  
      Praziquantel resistance risk factors survey.     Twenty  household 
surveys were conducted in each of the three administrative 
villages (60 total surveys; natural villages 1 and 6 and one each 
in administrative villages 1, 2, and 3, respectively) to ascertain 
social and cultural factors that relate to aspects of villagers’ 
perception: the role of key players in schistosomiasis diagnosis 
and treatment, the experience with praziquantel drug therapy; 
knowledge of schistosomiasis in terms of infection and 
prevention, access to and use of clean water and latrines, and 
contact with unsanitary water. Households were recruited 
randomly based on the availability of household members 
during the time surveys, which was a weekday morning in 
January. One person was selected from the household to 
complete the survey. 
  The first section of the survey assessed the roles of the 
schistosomiasis control station, village leader, villager doc-
tor, family, and school when villagers become infected and 
need diagnosis or treatment. The second section assessed vil-
lagers’ experiences with praziquantel by understanding their 76 SETO AND OTHERS
drug treatment compliance, others who may play a role in 
their compliance, the convenience of acquiring the drug, their 
experience with side effects of the drug, and whether the side 
effects affect their daily lives. The third section evaluated vil-
lagers’ knowledge of schistosomiasis transmission and preven-
tion methods and also asked which prevention methods, if any, 
that they used. The fourth section investigated water and sani-
tation with two subsections: presence of latrines and biogas 
systems and access to clean water versus contact with unsani-
tary water. 
  Ethical approval for this study was provided by the 
University of California Committee for the Protection of 
Human Subjects, and written informed consent was obtained 
for participation. 
   Statistical  analyses.     Between-group differences in infection 
prevalence and between-group survey responses were assessed 
by Fisher’s exact test. To assess the associations between infec-
tion and various factors related to schistosomiasis perception, 
drug treatment experience, knowledge of transmission, and 
exposure, logistic regression was used to estimate the odds ratio 
(OR) of self-reported history of infection as a function of the 
responses to the questions in the risk factors survey. History of 
infection was defined as an affirmative response to the question 
“Have you previously been infected?” We used history of 
infection rather than current infection because of the small 
numbers of current infections in the 60 household samples. 
Models were fit individually to each survey question variable, 
unadjusted and adjusted for age, gender, and income. Within 
administrative village, correlation was accounted for using 
generalized estimating equations (GEE) with exchangeable 
correlation and inference from robust variance estimates. 
  P   values less than 0.05 were considered statistically significant. 
Analyses were conducted using Stata v.10 (StataCorp, College 
Station, TX). 
    RESULTS 
  Infection  results.     Of the registered village residents, 5,862 
were eligible for the study, and 3,269 (56%) participated in 
the infection survey. The low participation rate was expected 
because of individuals leaving their village to work in cities. 
Generally, the age of the missing individuals was centered at 25 
years of age. Of the study participants, 185 (5.7%) were found 
to be infected. Of those that participated, 3,153 had complete 
age, sex, and infection data, which are summarized in   Table 1   
and   Figure 1  . Although there were relatively low numbers 
examined in the lowest age group (< 10 year olds), they had 
the lowest levels of infection. Conversely, the highest infections 
were found in the 30–39 and 60+ age groups. Infection tended 
to be higher in males than females for most age groups, except 
most notably for the 40–49 year olds. 
          Infection prevalence for natural villages ranged from 0% 
to 17% (  Table 2  ), with prevalences of 7.7%, 2.6%, and 5.9% 
in administrative villages 1, 2, and 3, respectively. Prevalence 
of infection was notably lower in the four natural villages 
for which historical data were available from 2000 and 2002 
(  P   < 0.001). 
            The Kato–Katz examination had less sensitivity to detect 
eggs than the hatch test. Of the 185 found to be hatch test-
positive, 177 participated in the Kato–Katz examination, 
and 108 (61%) were Kato–Katz-negative. Overall, mean egg 
excretion was 22 EPG (standard deviation [SD] = 97, range 
 Table 1 
    Infection prevalence by age and gender   
Age (years)
Examined Infected Prevalence of infection
Female Male   N Female Male   N  Female (%) Male (%) Percent
4–9 51 62 113 0 4 4 0.0 6.5 3.5
10–19 278 313 591 5 24 29 1.8 7.7 4.9
20–29 179 157 336 9 9 18 5.0 5.7 5.4
30–39 317 303 620 20 25 45 6.3 8.3 7.3
40–49 433 351 784 32 14 46 7.4 4.0 5.9
50–59 247 240 487 11 10 21 4.5 4.2 4.3
60+ 93 129 222 4 15 19 4.3 11.6 8.6
Total 1,598 1,555 3,153 81 101 182 5.1 6.5 5.8
 Figure 1.        Age distribution of participants and infection prevalence.       77 PRAZIQUANTEL RESISTANCE IN CHINA
= 0–1,263), whereas for those with positive Kato–Katz results, 
the mean excretion was 58 EPG (SD = 151, range = 8–1,263). 
  After treatment with two 40-mg/kg doses praziquantel, only 
1 of 185 original hatch test-positive persons was found to still 
be hatch-positive on reexamination after 1 month. After a sec-
ond treatment with two 40-mg/kg doses praziquantel, the per-
son was no longer found to be infected. 
   Miracidial  assay  results.       Table 3   shows the results of   in vitro  
tests of miracidial susceptibility to different praziquantel 
concentrations and exposure times. Susceptibility was deter-
mined by a characteristic shape change that occurs to the 
miracidia when exposed to praziquantel as described by Liang 
and others.  16   A relatively small number of parasites was available 
for the   in vitro   test because of the low levels of infection and 
miracidia recovered from hatch tests. At each concentration, 
the percent of normal (shape unchanged) miracidia generally 
decreased with exposure time, except in the control groups. 
Also, for each exposure time (column), the percent of normal 
miracidia decreased with higher concentrations. The EC  50   was 
found to lie between 10  −8   and 10  −7   M for 10 minutes of exposure 
and 10  −7   and 10  −6   M for 5 minutes of exposure, respectively. At 
the highest concentration, one miracidia was found to remain 
unchanged up to the maximum of 10 minutes exposure. 
       Resistance  factors  survey  results.     Sixty household surveys 
were completed. The demographics of the participants are pre-
sented in   Table 4   for each of the three administrative villages. 
 Table 2 
    Infection prevalence by village in 2009 and in a subset of villages in 2000 and 2002 surveys   
Administrative village Natural village Examined Hatch positive Prevalence of infection (%) Prevalence of infection in 2002 (%) Prevalence of infection in 2000 (%)
1 1 163 10 6.1
1 2 153 5 3.3
1 3 110 3 2.7
1 4 115 9 7.8
1 5 91 11 12
1 6 115 8 7.0 32 65
1 7 73 5 6.8
1 8 53 5 9.4
1 9 90 4 4.4
11 0 7 1 1 2 1 7
11 1 6 0 6 1 0
1 12 94 6 6.4
11 3 7 9 1 3 1 6
Village 1 total 1,267 97 7.7
2 1 43 2 4.7
2 2 108 1 0.9
2 3 89 1 1.1
2 4 103 2 1.9
2 5 85 4 4.7 28 68
2 6 118 8 6.8
2 7 98 3 3.1
2 8 159 0 0.0
2 9 47 0 0.0
2 10 50 2 4.0
Village 2 total 900 23 2.6
3 1 94 2 2.1
3 2 140 4 2.9
3 3 164 11 6.7 23 44
3 4 149 8 5.4
3 5 103 7 6.8
3 6 105 9 8.6
3 7 123 8 6.5 38 73
3 9 56 3 5.4
3 10 74 1 1.4
31 1 9 4 1 2 1 3
Village 3 total 1,102 65 5.9
Total 3,269 185 5.7
    Difference between years was significant (Fisher’s exact test;   P   < 0.001).   
 Table 3 
    Miracidial susceptibility to different praziquantel concentrations and exposure times   
Praziquantel concentration (M) Miracidia number
Shape unchanged after exposure period (in minutes)
1234579 1 0
Control (water) 5 100% 100% 100% 100% 100% 100% 100% 100%
DMSO 10  −3 5 100% 100% 100% 100% 100% 100% 100% 100%
10  −8 5 100% 100% 100% 100% 100% 100% 80% 60%
10  −7 21 100% 95% 86% 81% 71% 57% 48% 33%
10  −6 24 96% 71% 50% 33% 29% 21% 13% 13%
10  −5 5 100% 100% 40% 20% 20% 20% 20% 20%78 SETO AND OTHERS
Generally, the age, economic status, educational attainment, 
and occupations of participants were similar across villages 
(  P  > 0.05), although a larger proportion of females participated 
in one of the villages (  P   = 0.025 between villages 1 and 3) and 
another village included participation of those with business 
occupations (typically, those operating small stores). 
     The assessed risk factors related to potential development of 
praziquantel resistance are summarized in   Table 5  . Although 
there were statistically significant differences in the responses 
related to roles and responsibilities for schistosomiasis diag-
nosis and treatment across administrative villages, generally, 
most stated that the schistosomiasis control station had the 
greatest responsibility, despite the availability of praziquan-
tel at rural village doctor’s clinics. Despite greater responsi-
bility assigned to the control station, roughly two-thirds of 
respondents reported that they seek treatment from the vil-
lage doctor, and roughly one-third reported that treatment is 
obtained from township leaders, who are often recruited by 
the control station to administer drug treatments to their resi-
dents. Moreover, the majority responded that the local village 
leaders played an active role in reminding villagers to take 
the drug. 
      Roughly  one-half  of  respondents  reported  that  they 
had been previously infected with schistosomiasis, which 
is expected given that the township historically has been a 
high-endemic area. The differences in self-reported infec-
tion history between administrative villages were significant 
(  P   = 0.015). However, self-reported infection was higher and 
rank was ordered differently for villages than current infec-
tion levels assessed from the hatch tests. This suggests that 
drug treatment has been quite intense in this area, but rein-
fection has occurred differentially between villages. There was 
no significant differences between villages in the amounts of 
treatment in recent years, with the majority of participants 
reported taking the drug three times in the past 3 years, which 
corresponded to the schistosomiasis control station’s annual 
chemotherapy administrations aimed at reaching transmission 
control status in the province. 
  Participants reported that the drug is readily available and 
reported good drug compliance, with nearly all reporting that 
they take the entire dose of drug. Most took the drug immedi-
ately, and those that did not reported that they took the drug 
at night before bedtime, which is sometimes recommended 
by control staff to alleviate side effects. Roughly one-half of 
respondents experienced some side effects from praziquantel. 
The reported symptoms were generally mild (lightheadedness, 
vomiting, stomach ache, dehydration, and chills). However, 
one-third of respondents reported that these effects were seri-
ous enough to affect work. The reporting of side effects that 
affected work was strongly positively associated with num-
ber of previous treatments in the past 3 years (OR = 335, 
  P   < 0.001, 95% confidence interval [CI] = 299–376). In addi-
tion, we found that males were less likely to report side effects 
(OR = 0.32,   P   = 0.003, 95% CI = 0.15–0.68). There were no 
significant differences in reported drug treatment behavior or 
side effects between villages. 
  The responses to the questions about knowledge and pre-
vention of schistosomiasis as well as questions about clean 
water and sanitation suggest that schistosomiasis reinfec-
tion may continue to be a problem in this area. Despite most 
reporting that contact with unsafe water is associated with 
infection, more than one-third of participants incorrectly 
reported that transmission had to do with drinking unclean 
water, and another 8% reported that they did not know how 
infection occurred. Additionally, approximately one-quarter 
of respondents felt that there was nothing that they could do 
to avoid infection. Despite all participants reporting that they 
had access to clean piped water, contact with unsanitary water 
sources was still high for a variety of common activities. Also, 
the majority of participants felt it was acceptable to defecate 
outdoors in the wild. 
 There were promising responses in terms of the potential for 
rural development and environmental modification to reduce 
the risk of infection. Nearly one-half of respondents reported 
having biogas toilets, which has been previously found to 
reduce the risk of schistosomiasis as well as be highly accepted 
by villagers.  22   Additionally, there was very good understand-
ing of the potential role that bovine populations play in schis-
tosomiasis transmission, which led to many suggesting that 
removal of cow stool from the environment may be a worth-
while endeavor. 
  To gauge the impact of schistosomiasis treatment, percep-
tion, knowledge, and behaviors on infection, we estimated 
the unadjusted and age-, gender-, and income-adjusted OR 
of self-reported historical infection for each survey question 
(  Table 6  ). Although treatment side effects and drug-  taking 
behavior were not significantly associated with historical 
infection, the OR of historical infection was lower among 
those that relied on local village doctors than the control 
station. Conversely, the OR was higher for those that had a 
better knowledge of one of the preventative measures (gloves; 
e.g., when washing clothes or vegetables in potentially infec-
tive ditch water), with the positive correlation perhaps sug-
gestive that prevention health education messages have been 
effectively delivered to individuals at greatest risk. Finally, 
the highest ORs were estimated for various exposure factors, 
including contact with ponds and contacts related to cook-
ing and drinking, washing vegetables, and bathing activities, 
suggesting that continued exposure remains a large driver of 
ongoing infection. 
 Table 4 
    Demographic characteristics of resistance factors survey participants 







  N 20 20 20
Gender (% female) 35 40 75
Mean age in years 42 46 39
 SD 10 11 9
 Range 21–63 13–61 23–56
Economic status (%)
 Low 10 35 25
 Medium 85 65 75
 High 5 0 0
Educational attainment (%)
 None 5 5 10
  Less than elementary 5 20 20
 Elementary 25 50 25
 Middle 60 20 45
 High 5 5 0
Occupation (multiple occupations allowed; %)
 Farmer 80 95 95
 Student 0 0 0
 Businessman 20 0 0
  Local government official 0 0 0
 Domestic  worker 40 55 5079 PRAZIQUANTEL RESISTANCE IN CHINA
 Table 5 
    Responses from the resistance risk factors survey   
Administrative village 1 Administrative village 2 Administrative village 3
All   P  Ratio Percent Ratio Percent Ratio Percent
A. Roles and responsibilities
1. Who is responsible for diagnosis and treatment? 0.058
Schistosomiasis control station 15/20 75% 20/20 100% 18/20 90% 88%
Village doctor 5/20 25% 0/20 0% 2/20 10% 12%
Village or township leader 0/20 0% 0/20 0% 0/20 0% 0%
2. Who is responsible for reducing the risk of infection? 0.002
Schistosomiasis control station 14/20 70% 19/19 100% 19/20 95% 88%
Village doctor 6/20 30% 0/19 0% 0/20 0% 10%
Village or township leader 0/20 0% 0/19 0% 1/20 5% 2%
3. If previously infected, who do you go to for treatment? 0.009
Schistosomiasis control station 0/6 0% 0/15 0% 0/6 0% 0%
Village doctor 1/6 17% 10/15 67% 6/6 100% 63%
Village or township leader 5/6 83% 5/15 33% 0/6 0% 37%
4. If previously infected, do you need a reminder to take the drug? 0.002
No, I do not need a reminder 6/6 100% 3/15 20% 2/6 33% 41%
Yes, village leader reminds me 0/6 0% 12/15 80% 4/6 67% 59%
B. History of infection and treatment
1. Has history of infection 7/18 39% 15/20 75% 6/19 32% 49% 0.015
2. How many times have you taken the drug in the past 3 years? 0.922
One time 0/6 0% 1/13 8% 0/6 0% 4%
Two times 1/6 17% 1/13 8% 0/6 0% 8%
Three times 4/6 67% 10/13 77% 6/6 100% 80%
Four times 1/6 17% 1/13 8% 0/6 0% 8%
C. Drug treatment experience
1. Has side effects from treatment 3/6 50% 10/15 67% 1/6 17% 52% 0.133
2. Side effects affect work 0/3 0% 4/9 44% 0/1 0% 31% 0.648
3. It is convenient to get treatment 6/6 100% 15/15 100% 5/5 100% 100% –
4. Consumes the drug immediately  *  6/6 100% 8/15 53% 3/5 60% 65% 0.124
5. It is important to consume the entire dose 6/6 100% 14/15 93% 5/5 100% 96% 1
D. Knowledge and prevention of schistosomiasis
1. How is schistosomiasis transmitted? (multiple answers allowed)
Contact with irrigation ditches, lakes, and ponds 12/20 60% 19/20 95% 18/20 90% 82% 0.019
Swimming 6/20 30% 13/20 65% 10/20 50% 48% 0.101
Drinking unsanitary water 4/20 20% 10/20 50% 9/20 45% 38% 0.127
Something related to snails 5/20 25% 9/20 45% 9/20 45% 38% 0.36
Do not know 4/20 20% 0/20 0% 1/20 5% 8% 0.115
2. How can you prevent infection? (multiple answers allowed)
Wear rain boots in infection risk areas 14/20 70% 13/20 65% 16/20 80% 72% 0.675
Wear gloves 6/20 30% 13/20 65% 9/20 45% 47% 0.1
Preventative medicine/plaster 0/20 0% 0/20 0% 1/20 5% 2% 1
No way 5/20 25% 6/20 30% 3/20 15% 23% 0.641
E. Clean water and sanitation
1. What kind of toilet do you have? 0.033
Simple toilet 7/20 35% 6/19 32% 9/15 60% 41%
Sanitary toilet 3/20 15% 0/19 0% 3/15 20% 11%
Biogas toilet 10/20 50% 13/19 68% 3/15 20% 48%
2. Shares a toilet with other households 5/18 28% 1/12 8% 0/13 0% 14% 0.068
3. Does not mind going to the bathroom outdoors in the wild 9/20 45% 17/20 85% 11/20 55% 62% 0.026
4. Aware that schistosomiasis is transmitted by cow stool 6/6 100% 12/12 100% 4/4 100% 100% –
5. Believes cow stool should be removed 4/6 67% 10/12 83% 2/3 67% 76% 0.643
6. Has access to clean piped water 20/20 100% 20/20 100% 19/19 100% 100% –
7. How do you use clean water? (multiple answers allowed)
Cooking and drinking 20/20 100% 20/20 100% 19/19 100% 100% –
Washing vegetables 20/20 100% 20/20 100% 16/19 84% 95% 0.03
Bathing 20/20 100% 17/20 85% 15/19 79% 88% 0.084
Washing laundry 16/20 80% 17/20 85% 15/19 79% 81% 0.919
8. Has contact with unsanitary water 17/20 85% 18/19 95% 17/20 85% 88% 0.68
9.   Where do you contact unsanitary water? (multiple answers 
allowed)
River 7/17 41% 14/18 78% 6/17 35% 52% 0.026
Pond 4/17 24% 12/18 67% 7/17 41% 44% 0.04
Ditches 14/17 82% 17/18 94% 17/17 100% 92% 0.205
Reservoirs 0/17 0% 1/18 6% 0/17 0% 2% 1
  10. How do you use unsanitary water? (multiple answers allowed)
Cooking and drinking 4/17 24% 12/18 67% 6/17 35% 42% 0.032
Washing vegetables 4/17 24% 12/18 67% 8/17 47% 46% 0.04
Bathing 4/17 24% 13/18 72% 7/17 41% 46% 0.015
Washing laundry 7/17 41% 14/18 78% 9/17 53% 58% 0.088
    *     Those that responded no and said that they consumed the drug at night.   80 SETO AND OTHERS
        DISCUSSION 
  This study presents data on current   S. japonicum   suscepti-
bility to praziquantel and risk factors for the development of 
drug resistance in a region of China where transmission con-
trol was recently attained through intense chemotherapy. We 
found considerably lower prevalence and mean intensity of 
infection than in previous surveys conducted in 2000 and 2002. 
Based on infectious disease modeling work, we feel that the 
dramatic reductions in infection largely have been because of 
annual chemotherapy but also because of control of snail popu-
lations and complementary policies and interagency coordina-
tion, which have allowed the introduction of improved biogas 
sanitation to this area.  23   Although the county as a whole has 
achieved the status of transmission control, in our 33 study vil-
lages, the infection prevalence was 5.7%. This is, however, still 
quite low. Of the 185 persons found to be infected and treated, 
only one failed treatment was suspected. This is remarkable 
considering the cure rates of 80–90% reported in the   S. japoni-
cum   literature. 14   The high efficacy may be in part because of 
the low levels of infection in this region or infection being 
reduced to undetectable low levels. 
  The epidemiologic patterns of infection in our study reflect 
the current transmission situation and ongoing control chal-
lenges found in Sichuan. Although infection was lower than 
in previous studies in this area, the patterns of infection with 
age were similar, with the prevalence of infection not high-
est in the youngest age groups but rather, in mid-aged adults 
and older populations. Participation for the young adult age 
group was low, because many of these people no longer live 
in their villages but spend large amounts of time away work-
ing in cities. This is a phenomenon that we have seen in recent 
infection surveys conducted in other parts of the province, 
and we are actively studying them to determine the extent 
to which this population group may be harboring infection, 
and if so, whether they may reinitiate infection in controlled 
areas when they return to their villages. Additionally, some of 
the infection statistics in our study reflect the diagnostics that 
we used. For example, in our study, the Kato–Katz failed to 
measure eggs in 61% of people who had tested positive in the 
hatch test. This strongly suggests the need for better diagnostic 
tools if we are to continue to track the efficacy of chemother-
apy and other types of control activities in low-transmission 
settings. 
 Our   in vitro   tests of miracidia found limited evidence for 
reduced parasite susceptibility to praziquantel. A small num-
ber of parasites were found to survive prolonged and high 
concentrations of praziquantel. Additionally, comparing our 
EC  50   results with those of Liang and others  16   suggests that 
Sichuan parasites may have less susceptibility to praziquantel 
than those found in other provinces.  16   For example, for Hunan 
province parasites, at 5 minutes of exposure, 0% and 64% of 
miracidia were unchanged for concentrations 10  −6   and 10  −7   M. 
For Jiangxi province parasites, 0% and 60% of miracidia were 
unchanged for the same exposure and concentrations. For 
Hubei province parasites, 0% and 63% were unchanged. We 
found 29% and 71%, although we tested much smaller num-
bers of miracidia. The fact that only one treatment failure was 
suspected from our epidemiologic study suggests that labora-
tory evidence of diminished sensitivity to praziquantel may 
have negligible effect on real-world efficacy of control pro-
grams in this region of China but again, with the caveat that 
this population had very low-level infection. 
 Our   in vitro   study was limited by the numbers of miracidia 
that we were able to recover from the hatch tests. Previous 
studies have relied on either higher infection areas and/or 
laboratory-maintained lifecycles to obtain larger numbers of 
miracidia for such work. Despite our low sample numbers, we 
found relatively consistent concentration response profiles 
for increased susceptibility with increasing exposure time and 
increasing concentration of praziquantel. 
  Our laboratory work reflects the need for a relatively simple 
assay of parasite changes that may be occurring from prazi-
quantel treatments. Although we lack evidence of this, treat-
ment may also be responsible for functional changes in the 
parasite population (e.g., impaired mating, reduced fecundity, 
 Table 6 
    Risk factors for self-reported history of infection   
Age-, sex-, and income-adjusted Unadjusted
OR   P 95%  CI OR   P 95%  CI
Village doctor is responsible for treatment 0.27 < 0.001 0.18–0.42 0.23 < 0.001 0.15–0.36
Village doctor is responsible for reducing the risk of infection 0.23 < 0.001 0.15–0.33 0.19 < 0.001 0.14–0.28
Number of treatments in the past 3 years 0.48 0.254 0.13–1.70 0.75 0.043 0.56–0.99
Reported treatment side effects 2.52 0.426 0.26–24.4 2.59 0.396 0.29–23.3
Consumes drug immediately 2.12 0.398 0.37–12.2 1.38 0.412 0.64–3.01
Poor knowledge (drinking is responsible for infection) 0.74 0.512 0.30–1.81 0.80 0.19 0.58–1.12
Poor knowledge (does not know how infection occurs) 1.21 0.82 0.23–6.42 0.95 0.935 0.30–3.03
Boots prevent infection 1.06 0.937 0.24–4.60 0.90 0.872 0.26–3.18
Gloves prevent infection 3.63 0.027 1.16–11.4 2.90 0.177 0.62–13.6
No way to prevent infection 1.15 0.88 0.19–6.96 1.34 0.638 0.39–4.62
Sanitary toilet 0.35 0.12 0.09–1.31 0.33 0.009 0.14–0.76
Biogas toilet 0.88 0.891 0.14–5.54 0.89 0.858 0.24–3.23
Does not mind going to bathroom outdoors in the wild 1.34 0.76 0.21–8.67 1.30 0.706 0.33–5.18
Contacts unsanitary water 1.64 0.656 0.19–14.4 1.73 0.553 0.28–10.6
Contacts unsanitary water (river) 2.08 0.376 0.41–10.4 1.85 0.363 0.49–6.94
Contacts unsanitary water (pond) 4.58 0.005 1.58–13.3 2.96 0.001 1.54–5.71
Contacts unsanitary water (ditch) 0.95 0.92 0.37–2.46 1.11 0.837 0.43–2.87
Contacts unsanitary water (cooking and drinking) 3.46 0.004 1.48–8.07 2.44 < 0.001 1.86–3.22
Contacts unsanitary water (washing vegetables) 3.61 0.012 1.32–9.83 2.47 < 0.001 1.61–3.77
Contacts unsanitary water (bathing) 5.21 0.001 1.92–14.1 3.55 < 0.001 2.17–5.79
Contacts unsanitary water (washing laundry) 1.90 0.442 0.37–9.75 1.67 0.399 0.51–5.5081 PRAZIQUANTEL RESISTANCE IN CHINA
greater susceptibility to within-host density dependence, or 
less competent larval stages, all of which may be responsible 
for temporal changes in epidemiology that we have seen in 
our field site). Given the continued reliance on chemotherapy, 
a greater understanding of the occurrence of these population 
changes is warranted. Related work by Lamberton and oth-
ers  24  , who used the same   in vitro   assay on   S. mansoni   isolates, 
provides further motivation for the routing use of the method 
as a screening tool to identify population structure changes 
in schistosome-endemic regions where control programs are 
operating. 
  Although our risk factors survey recruited households ran-
domly from each of the three administrative villages in the 
township, participation was likely biased based on the avail-
ability of the villagers. Because of limited field resources, the 
number of participants in our survey was low. However, we 
had participation from both genders as well as a wide range of 
ages and a good representation of farmers, which   constitute 
the predominant occupation and risk group in the area. 
Because of this, we feel that the responses generally reflect 
the knowledge, attitude, behavior, and experience of villag-
ers in this region, including those with a history of infection, 
because more than one-third of respondents reported previ-
ous infection. 
  The responses from the risk factors survey may have several 
implications for the development of praziquantel resistance 
over time. First, chemotherapy treatments have been intense, 
with almost all respondents reporting annual treatments, which 
may create treatment fatigue and non-compliance over time. 
Although availability of the drug and compliance still seem 
high, there is concern that the high rates of side effects may 
further contribute to non-compliance in the future. Although 
other studies have found evidence of harsher side effects of 
praziquantel treatment with high intensity infections, our find-
ing of roughly one-half of respondents reporting mild side 
effects is consistent with other   S. japonicum   studies conducted 
on low- to middle-intensity infection populations.  1,  11,  25   For 
example, adverse effects were found in 58% of light infections 
in Japanese patients (treated with three 20-mg/kg doses).  6  
Santos and others  26   found similar percentages of adverse 
reactions (53.3% and 61.5% for 3 × 20-mg/kg treatment of 
light infections and patients with hepatosplenic involvement, 
respectively) in the Philippines.  26   In China, Wu and others  27  
found adverse side effects in 62% of treated patients, which 
is higher than we found. However, their study population 
had higher pre-treatment infection intensity (as measured by 
EPGs) than our study. The previous Japanese, Philippines, and 
Chinese studies also found that side effects tended to be mild. 
Despite generally mild effects, of particular concern for ongo-
ing treatment compliance is our finding of dramatically higher 
rates of more adverse work-affecting effects reported among 
those that had received more treatments in the last 3 years and 
the higher rate of effects among some risk groups (females). 
  The roles and responsibilities for diagnosis and treatment 
vary between parties. We found that much of the responsibil-
ity was placed on the schistosomiasis control station, but some 
key tasks were placed on village doctors (treatment and reduc-
ing infection) and local leaders (treatment and reminding vil-
lagers to take the drug). Our finding of an inverse relationship 
between self-reported history of infection and perceptions of 
village doctors’ role in treatment and prevention confirms the 
importance of control station activities in reducing infection 
in highly endemic populations, but it also suggests an oppor-
tunity for local entities to play a larger role in control. These 
entities must work in concert to make sure that all infected 
individuals comply with infection testing and drug administra-
tion if treatment failures are to be minimized. 
  The survey responses indicate gaps in schistosomiasis health 
education and poor attitudes to making behavioral changes to 
reduce exposure and contamination, which may contribute to 
ongoing infection. However, some preventative health educa-
tion messages, such as wearing gloves (e.g., to avoid parasite 
exposure during clothes- and vegetable-washing activities) 
seem to have been understood by the previously infected pop-
ulations. Despite access to clean water among all participants 
in the survey, contact with unsanitary water (irrigation ditches, 
lakes, and ponds) remains high and is perhaps inevitable given 
the rural agrarian lifestyle in this region. Notably, current 
exposure to unsanitary water through a variety of activities 
remains high among those that have been historically infected. 
Rural development in the form of sanitation and environmen-
tal modifications seemed to be a positive complement to the 
chemotherapy program. These modifications include the rela-
tively high prevalence of biogas toilets and the recognition that 
bovines are reservoir hosts whose stool needs to be managed. 
Snail control using molluscicides, which was not specifically 
addressed in the survey, was another complementary strategy 
in the recent control work in this region. Control of the inter-
mediate host likely had an effect on reducing infection, at least 
in the short term. On the whole, given the persistence of many 
risk factors, there is concern that infection levels may return 
to their previous levels. Hence, surveillance and treatment of 
infection will remain important and necessary strategies to 
maintaining low levels of infection in this area. In the short 
term, at least with the low levels of infection in this region, 
praziquantel remains an effective drug for treatment.       
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